Home › Triple-Negative Breast Cancer › New Mexico › Albuquerque
Triple-Negative Breast Cancer clinical trials in Albuquerque, NM
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Albuquerque (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0090), Albuquerque
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- University of New Mexico, Albuquerque
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Albuquerque
- Non-Small Cell Lung Cancer18 studies
- Breast Cancer17 studies
- Ovarian Cancer15 studies
- Cancer (all types)14 studies
- Lung Cancer14 studies
- Metastatic Cancer12 studies
- Endometrial Cancer12 studies
- Type 2 Diabetes11 studies
- Cardiovascular Disease10 studies
- Melanoma9 studies
- Acute Myeloid Leukemia9 studies
- Prostate Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.